In this preclinical study the newly found mutation in 11% of liver cancer cells may explain resistance to currently available treatments. In the discussion section Tykerb (Lapatinib) is mentioned as possibly effective against liver cancer.
http://www.biomedcentral.com/1471-2407/6/278
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma